Literature DB >> 1968719

Rebound insomnia: its determinants and significance.

T Roehrs1, G Vogel, T Roth.   

Abstract

Rebound insomnia is a sleep disturbance that occurs on discontinuation of benzodiazepine hypnotic drugs. It has been reported in both patients and healthy normal subjects and is characterized by increased wakefulness above the person's baseline levels. This article reviews that available information regarding determinants, possible mechanisms, and clinical significance of rebound insomnia. It is concluded that rebound insomnia is a disturbance of one or two nights' duration that primarily follows discontinuation of short- to intermediate-acting benzodiazepines. It occurs at high doses of a given drug, beyond which no additional hypnotic efficacy is evident. There seem to be clear individual differences in the experience of rebound insomnia, but no prospective studies have established which differences predict rebound. It is likely to be avoided by initiating treatment with the lowest effective dose and tapering the dose upon discontinuation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1968719     DOI: 10.1016/s0002-9343(13)80001-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  12 in total

Review 1.  Hypnotics: an update.

Authors:  Timothy Roehrs; Thomas Roth
Journal:  Curr Neurol Neurosci Rep       Date:  2003-03       Impact factor: 5.081

2.  Rebound insomnia in normals and patients with insomnia after abrupt and tapered discontinuation.

Authors:  T Roehrs; L Merlotti; F Zorick; T Roth
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Hypnotics. Drug selection by means of the System of Objectified Judgement Analysis (SOJA) method.

Authors:  R Janknegt; A van der Kuy; G Declerck; C Idzikowski
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

Review 4.  Hypnotics and sleep physiology: a consensus report. European Sleep Research Society, Committee on Hypnotics and Sleep Physiology.

Authors:  A A Borbély; T Akerstedt; O Benoit; F Holsboer; I Oswald
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

Review 5.  Interactions between disordered sleep, post-traumatic stress disorder, and substance use disorders.

Authors:  Ryan Vandrey; Kimberly A Babson; Evan S Herrmann; Marcel O Bonn-Miller
Journal:  Int Rev Psychiatry       Date:  2014-04

Review 6.  Clinical management of patients with insomnia. The role of zopiclone.

Authors:  G Hajak; A Rodenbeck
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

Review 7.  Zopiclone: is there any dependence and abuse potential?

Authors:  M Lader
Journal:  J Neurol       Date:  1997-04       Impact factor: 4.849

8.  Rebound insomnia and hypnotic self administration.

Authors:  T Roehrs; L Merlotti; F Zorick; T Roth
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 9.  Rebound insomnia and newer hypnotics.

Authors:  M Lader
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  Insomnia in general practice : a consensus report produced by sleep specialists and primary-care physicians in Italy.

Authors:  Mario Giovanni Terzano; Liborio Parrino; Enrica Bonanni; Fabio Cirignotta; Franco Ferrillo; Gian Luigi Gigli; Mariantonietta Savarese; Luigi Ferini-Strambi
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.